Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
Public ClinicalTrials.gov record NCT02301143. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Nab-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer.
Study identification
- NCT ID
- NCT02301143
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 107 participants
Conditions and interventions
Conditions
Interventions
- nab-Paclitaxel Drug
- Gemcitabine Drug
- Chemoradiation Drug
- Capecitabine Drug
- Surgery Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 21, 2015 (Actual)
- Primary completion
- Nov 21, 2017 (Actual)
- Completion
- Apr 26, 2018 (Actual)
- Last update posted
- Mar 20, 2019
2015 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Arizona | Scottsdale | Arizona | 85259 | — |
| UC Davis Cancer Center | Sacramento | California | 95817 | — |
| Scripps Clinic Torrey Pines | San Diego | California | 92037 | — |
| Smilow Cancer Hospital At Yale-New Haven | New Haven | Connecticut | 06510 | — |
| Georgetown University Medical Center Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Piedmont Cancer Institute PC | Atlanta | Georgia | 30318 | — |
| Cancer Treatment Centers of America - Southeastern Regional Medical Center | Newnan | Georgia | 30265 | — |
| ME Center for Cancer Medicine | Scarborough | Maine | 04074 | — |
| Tufts - New England Medical Center | Boston | Massachusetts | 02111 | — |
| University of Massachusetts | Worcester | Massachusetts | 01655 | — |
| Saint Joseph Mercy Ann Arbor Hospital | Ann Arbor | Michigan | 48106 | — |
| Karmanos Cancer Center Wayne State University | Detroit | Michigan | 48201 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Regional Cancer Care Associates LLC | Morristown | New Jersey | 07962 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Clinical Research Alliance | Lake Success | New York | 11042 | — |
| State University of New York Upstate Medical Center | Syracuse | New York | 13215 | — |
| Montefiore Einstein Cancer Center | The Bronx | New York | 10461 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Mark H Zangmeister Center | Columbus | Ohio | 43219 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-5505 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02301143, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2019 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02301143 live on ClinicalTrials.gov.